Paper Details

  1. Home
  2. Paper Details

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials.

Author: LeeL Y, TongC Y W, WilkinsonM, WongT

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Hepatitis C virus (HCV) affects millions globally. Current treatment with pegylated interferon and ribavirin is associated with side effects, causing 10% of patients to stop treatment and 30% to require dose reduction. For patients with genotype 1 HCV, only 40% achieve undetectable viral levels after treatment.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) affects approximately 3% of the world population. The current standard of care for treatment of HCV is a combination of pegylated interferon and ribavirin. Approximately 10% of patients will stop treatment and 30% of patients require dose reduction because of side effects. Fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1742-1241.2012.02895.x

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Hepatitis C Treatment

Hepatitis C virus (HCV) affects a significant portion of the global population, posing a significant health challenge. The standard treatment for HCV has been a combination of pegylated interferon and ribavirin, but its effectiveness and tolerability have proven to be a desert of limitations. This review meticulously examines the emerging therapies for chronic HCV infection, exploring the latest clinical trial data and promising new horizons in treatment approaches.

Seeking a New Oasis in HCV Treatment

The review reveals that while the current standard of care for HCV treatment has shown some success, it faces significant limitations. A significant percentage of patients experience side effects, leading to treatment discontinuation or dose reductions. Moreover, the treatment efficacy for genotype 1 HCV infection remains below optimal levels. This review provides a valuable roadmap for navigating the ever-changing landscape of HCV therapy, highlighting the need for new and more effective treatment strategies.

A New Dawn for HCV Treatment?

This review underscores the urgent need for new and improved therapies for HCV infection. The limitations of the current standard of care highlight the importance of continued research and development in this area. It's like a relentless desert wind, urging us to discover new ways to combat this persistent viral threat. The potential of emerging therapies, like those targeting specific viral proteins, offers a beacon of hope for the future of HCV treatment. This research is a vital step in the journey towards a brighter future for HCV patients.

Dr.Camel's Conclusion

This comprehensive review serves as a vital guide in the ongoing quest for more effective and well-tolerated treatments for chronic HCV infection. The limitations of the current standard of care underscore the need for continued innovation, and the review highlights the promising potential of emerging therapies. As we venture deeper into the desert of HCV research, we must remain optimistic about the future of treatment and the potential to alleviate the burden of this virus.

Date :
  1. Date Completed 2012-05-23
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22420497

DOI: Digital Object Identifier

10.1111/j.1742-1241.2012.02895.x

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.